RESUMEN
The effects of dosing time on the anticoagulant activity of unfractionated heparin, low molecular weight heparin (nadroparin) and danaproid were investigated. The chronopharmacological comparisons of the drugs were done on the anti-Xa, anti-IIa activities and activated partial thromboplastin time assays. Several dosing times were considered and an analysis based on a population approach was adopted. Under unfractionated heparin, the pharmacological activities did not exhibit significant daily variations. In contrast, significant daily profiles were observed in all the biological assays performed with low molecular weight heparin. Anti-Xa and anti-IIa activities showed some fluctuations over a 24-hour period with a peak at noon. As for the variations of the activated partial thromboplastin time, two peaks were noted early in the morning and at the beginning of nightfall. As for danaproid, only a daytime maximum of anti-Xa activity could be found.
Asunto(s)
Sulfatos de Condroitina/farmacocinética , Cronoterapia/normas , Dermatán Sulfato/farmacocinética , Fibrinolíticos/farmacocinética , Heparina de Bajo-Peso-Molecular/farmacocinética , Heparina/farmacocinética , Heparitina Sulfato/farmacocinética , Animales , Sulfatos de Condroitina/administración & dosificación , Dermatán Sulfato/administración & dosificación , Relación Dosis-Respuesta a Droga , Factor Xa/metabolismo , Inhibidores del Factor Xa , Fibrinolíticos/administración & dosificación , Heparina/administración & dosificación , Heparina de Bajo-Peso-Molecular/administración & dosificación , Heparitina Sulfato/administración & dosificación , Masculino , Tasa de Depuración Metabólica , Modelos Biológicos , Nadroparina/administración & dosificación , Nadroparina/farmacocinética , Tiempo de Tromboplastina Parcial , Protrombina/antagonistas & inhibidores , Protrombina/metabolismo , Ratas , Ratas Sprague-DawleyRESUMEN
This report summarizes the results of some of the studies that have evaluated the pharmacokinetic, pharmacodynamic, anticoagulant, and antithrombotic properties of Sulodexide, which consists of a mixture of electrophoretically fast moving heparin (80% of the mass) and dermatan sulfate (the balance), with an average product (Mr) <8000. The low molecular weight (Mr) of the constituents of Sulodexide would predict that the product has the high bioavailability associated with low-Mr heparin and low-Mr dermatan sulfate. Given orally, subcutaneously, or by intravenous injection, Sulodexide exhibits antithrombotic and profibrinolytic properties in several animal models of venous and arterial thrombosis and has relatively high affinity for endothelial (and possibly other) cells. Additionally, in a large multicenter clinical trial involving 3986 patients who had recovered from acute myocardial infarction, oral Sulodexide was associated with a 32% reduction in death and a significant reduction of left ventricular thrombus formation. Compared with heparin, low-Mr heparin, and unfractionated and low-Mr dermatan sulfates, the doses of Sulodexide required for antithrombotic efficacy suggest that the combination of heparin and dermatan sulfate in Sulodexide provides a more effective antithrombotic mechanism than heparin/low-Mr heparins (which catalyze the antiprotease actions of antithrombin III) or dermatan sulfate/low-Mr dermatan sulfate (which catalyze thrombin inhibition by heparin cofactor II).